Teddy bears fitted with medical devices such as gastronomy (feeding) tubes may help normalize and lessen medical anxiety in children who need the same devices, according to a… read more.
Eli Lilly and Company announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and… read more.
Johnson & Johnson announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is… read more.
Bristol Myers Squibb announced positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) in 800 patients with multiple… read more.
Tiziana Life Sciences, Ltd. announced that it has submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy… read more.
Novo Nordisk presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver… read more.
Quest Diagnostics published a new study in The Journal of Molecular Diagnostics showing that the Haystack Mrd test is highly accurate at detecting residual and recurrent disease, demonstrating… read more.
AstraZeneca has entered into an agreement to invest $2 billion in newly issued equity in Summit Therapeutics Inc. to accelerate the development of ivonescimab, a first-in-class bispecific antibody… read more.
Telix Pharmaceuticals Limited announces that the first patients in the United States (U.S.) have been dosed with Pixclara (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron… read more.
Novo Nordisk announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the analysis, adults who escalated to semaglutide… read more.
Moberg Pharma AB announced the publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with Mob-015 was achieved across the… read more.
Novartis announced that the FDA approved Rhapsido (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
